Galderma Initiates U.S. Study Of Novel Muscle Relaxant For Aesthetic Dermatology And Cosmetic Surgery

LAUSANNE, Switzerland--(BUSINESS WIRE)--Galderma, a global healthcare company focused on dermatology, today announced that it has initiated a Phase II clinical trial of a novel muscle relaxant in the United States. The study is investigating the safety and efficacy of Galderma’s internally developed liquid formulation of botulinum toxin in the setting of aesthetic dermatology and cosmetic surgery and will add to the existing Galderma neurotoxin franchise.

“This trial initiation demonstrates Galderma’s commitment to innovation in the aesthetic market and is designed to strengthen and complement our current neurotoxin franchise,” said Humberto C. Antunes, President and CEO of Galderma. “Our current neurotoxin business, which includes Dysport and Azzalure, continues its strong performance in key markets around the world. The development of a liquid neurotoxin represents a significant advancement over existing commercial products and would allow us to further strengthen our position in the aesthetic category by better meeting physician and patient needs.”

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC